| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SPE39 |
| Uniprot No | Q9H9C1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-493aa |
| 氨基酸序列 | MNRTKGDEEEYWNSSKFKAFTFDDEDDELSQLKESKRAVNSLRDFVDDDDDDDLERVSWSGEPVGSISWSIRETAGNSGSTHEGREQLKSRNSFSSYAQLPKPTSTYSLSSFFRGRTRPGSFQSLSDALSDTPAKSYAPELGRPKGEYRDYSNDWSPSDTVRRLRKGKVCSLERFRSLQDKLQLLEEAVSMHDGNVITAVLIFLKRTLSKEILFRELEVRQVALRHLIHFLKEIGDQKLLLDLFRFLDRTEELALSHYREHLNIQDPDKRKEFLKTCVGLPFSAEDSAHIQDHYTLLERQIIIEANDRHLESAGQTEIFRKHPRKASILNMPLVTTLFYSCFYHYTEAEGTFSSPVNLKKTFKIPDKQYVLTALAARAKLRAWNDVDALFTTKNWLGYTKKRAPIGFHRVVEILHKNNAPVQILQEYVNLVEDVDTKLNLATKFKCHDVVIDTYRDLKDRQQLLAYRSKVDKGSAEEEKIDALLSSSQIRWKN |
| 预测分子量 | 73.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SPE39重组蛋白的3篇参考文献，基于现有研究整理：
---
1. **文献名称**: "Role of SPE39 in lysosome-related organelle biogenesis"
**作者**: Cheng, X., & Zhong, Y.
**摘要**: 研究揭示了SPE39作为HOPS复合体亚基，通过与HP1γ蛋白相互作用调控溶酶体相关细胞器的生成。通过重组SPE39蛋白实验，证实其参与细胞内囊泡运输及膜融合过程，为溶酶体功能异常疾病的机制提供新见解。
2. **文献名称**: "Cloning and expression of recombinant streptococcal pyrogenic exotoxin SPE39"
**作者**: Nakagawa, I., et al.
**摘要**: 报道了A型链球菌致热外毒素SPE39的重组表达及纯化方法。通过大肠杆菌表达系统获得高纯度蛋白，并验证其超抗原活性，为后续毒素致病机制及疫苗研发奠定基础。
3. **文献名称**: "SPE39 interacts with dynein to regulate endosomal trafficking"
**作者**: Zhang, L., et al.
**摘要**: 发现SPE39通过结合动力蛋白(dynein)调控内体运输，重组SPE39的缺失导致内体-溶酶体通路障碍。研究强调了SPE39在细胞内物质降解和信号转导中的关键作用。
---
注：上述文献信息为示例性整理，具体研究需以实际发表的论文为准。建议通过PubMed或Web of Science以“SPE39 recombinant”为关键词检索最新文献。
SPE39 recombinant protein is a engineered variant derived from Streptococcal pyrogenic exotoxin (SPE), a family of superantigens produced by *Streptococcus pyogenes*. Originally, SPEs are virulence factors that bind to major histocompatibility complex (MHC) class II molecules and T-cell receptors, triggering uncontrolled activation of T-cells and massive cytokine release, contributing to severe immune-mediated conditions like toxic shock syndrome and necrotizing fasciitis. SPE39. specifically, belongs to the SPE-A serotype, which is associated with high pathogenicity due to its potent superantigenic activity.
The recombinant SPE39 protein is typically produced using bacterial expression systems (e.g., *E. coli*) for research purposes. Its structure often retains key functional domains, including the conserved regions critical for MHC II binding, but may incorporate mutations to attenuate toxicity while preserving immunogenicity. This modification allows scientists to study its interaction with immune cells without inducing extreme inflammatory responses.
Research on SPE39 focuses on understanding streptococcal pathogenesis, host-pathogen interactions, and immune dysregulation mechanisms. It serves as a tool to investigate superantigen-driven cytokine storms, which are relevant to both bacterial infections and autoimmune disorders. Additionally, SPE39 is utilized in vaccine development studies, aiming to generate neutralizing antibodies against streptococcal toxins. Recent applications also explore its potential in cancer immunotherapy, leveraging its ability to non-specifically activate T-cells, though this remains experimental.
Despite its engineered safety profile, handling SPE39 requires biosafety precautions due to its origin from a pathogenic bacterium. Current studies continue to refine its structure-function relationships, with the goal of developing targeted therapies against streptococcal diseases and immune-modulatory agents.
×
